Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M102,196Revenue (TTM) $M37,719Net Margin (%)12.3Altman Z-Score2.0
Enterprise Value $M115,057EPS (TTM) $1.8Operating Margin %14.6Piotroski F-Score7
P/E(ttm)23.1Beneish M-Score-2.7Pre-tax Margin (%)13.5Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %-0.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.85-y EBITDA Growth Rate %-4.4Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow17.8y-y EBITDA Growth Rate %-3.8ROA % (ttm)4.2Higher Current Ratio y-yN
Dividend Yield %4.2PEG--ROE % (ttm)7.5Less Shares Outstanding y-yY
Payout Ratio %92.0Shares Outstanding M2,574ROIC % (ttm)6.7Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYKen Fisher 2016-12-31 Add$37.06 - $42.01
($39.4)
$ 39.701%Add 0.39%12,492,035
SNYBill Nygren 2016-09-30 Reduce-0.67%$37.83 - $42.63
($40.13)
$ 39.70-1%Reduce -42.05%3,170,000
SNYNWQ Managers 2016-09-30 Buy 0.19%$37.83 - $42.63
($40.13)
$ 39.70-1%New holding335,521
SNYBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Add0.19%$37.83 - $42.63
($40.13)
$ 39.70-1%Add 11.37%31,320,327
SNYDodge & Cox 2016-09-30 Add0.15%$37.83 - $42.63
($40.13)
$ 39.70-1%Add 7.45%59,267,298
SNYHOTCHKIS & WILEY 2016-09-30 Add0.1%$37.83 - $42.63
($40.13)
$ 39.70-1%Add 5.33%12,041,028
SNYKen Fisher 2016-09-30 Reduce-0.1%$37.83 - $42.63
($40.13)
$ 39.70-1%Reduce -8.76%12,443,197
SNYCharles Brandes 2016-09-30 Reduce-0.03%$37.83 - $42.63
($40.13)
$ 39.70-1%Reduce -1.19%3,557,856
SNYJohn Paulson 2016-09-30 Add0.01%$37.83 - $42.63
($40.13)
$ 39.70-1%Add 5.44%417,000
SNYJoel Greenblatt 2016-09-30 Reduce$37.83 - $42.63
($40.13)
$ 39.70-1%Reduce -7.57%32,879
SNYNWQ Managers 2016-06-30 Sold Out -1.22%$38.13 - $44.32
($40.99)
$ 39.70-3%Sold Out0
SNYDavid Dreman 2016-06-30 Add0.47%$38.13 - $44.32
($40.99)
$ 39.70-3%Add 980.43%20,204
SNYHOTCHKIS & WILEY 2016-06-30 Add0.23%$38.13 - $44.32
($40.99)
$ 39.70-3%Add 12.47%11,432,112
SNYJohn Paulson 2016-06-30 Buy 0.17%$38.13 - $44.32
($40.99)
$ 39.70-3%New holding395,500
SNYDodge & Cox 2016-06-30 Add0.07%$38.13 - $44.32
($40.99)
$ 39.70-3%Add 3.04%55,155,913
SNYBarrow, Hanley, Mewhinney & Strauss 2016-06-30 Reduce-0.06%$38.13 - $44.32
($40.99)
$ 39.70-3%Reduce -3.32%28,122,279
SNYCharles Brandes 2016-06-30 Add0.03%$38.13 - $44.32
($40.99)
$ 39.70-3%Add 1.24%3,600,731
SNYKen Fisher 2016-06-30 Add0.01%$38.13 - $44.32
($40.99)
$ 39.70-3%Add 0.67%13,638,183
SNYJoel Greenblatt 2016-06-30 Add$38.13 - $44.32
($40.99)
$ 39.70-3%Add 2.45%35,571
SNYCharles Brandes 2016-03-31 Add0.78%$38.37 - $42.65
($40.17)
$ 39.70-1%Add 61.76%3,556,721
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-58.21view
Sanofi10% Owner 2015-01-26Buy647,448$95-58.21view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-57.39view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-40.64view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67417.6view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    David Herro's Oakmark International Fund Fourth Quarter Letter Jan 11 2017 
    Something Strange Is Going On With Oral Insulin Dec 23 2016 
    Dodge & Cox Invests in 7 Positions in the 3rd Quarter Dec 19 2016 
    Warren Buffett’s Only Dividend Stocks With 4%-Plus Yields Nov 29 2016 
    World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
    First Eagle Investments Comments on Sanofi Oct 24 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Take a Look at Sanofi Oct 05 2016 
    John Paulson Trims Synergy Sep 23 2016 

    More From Other Websites
    Is Amgen’s Cardiovascular Segment Still a Growth Opportunity? Jan 24 2017
    Failed Mergers Cast Shadow on Sanofi's Future Jan 23 2017
    4:54 am Sanofi provides color on FX for Q4; sees limited impact on Q4 salese Jan 23 2017
    Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    INSIGHT: Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    INSIGHT: Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
    Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval Jan 18 2017
    Drugmakers in Davos shift focus to chronic diseases of poor Jan 18 2017
    Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad Jan 17 2017
    Sanofi: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes Jan 17 2017
    Key FDA Events to Watch Out for in Q1 Jan 17 2017
    5 Trump-Proof Pharma Dividends Up To 5.3% Jan 16 2017
    Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink Jan 13 2017
    Sanofi, ImmuNext Sign $500M Autoimmune Drug Pact Jan 13 2017
    Insulin Drug Offers Hope for MannKind Jan 12 2017
    Regeneron, Sanofi's Drug Manufacturing Plant Cleared Jan 12 2017
    Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases Jan 10 2017
    The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron... Jan 10 2017
    Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit Jan 10 2017
    Sanofi Sees No Opening to Actelion Talks After J&J Re-Entry Jan 09 2017
    Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries Jan 09 2017
    Sanofi and Regeneron to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding... Jan 05 2017
    Regeneron, Sanofi to appeal US judge's ban on cholesterol drug sales Jan 05 2017
    U.S. judge blocks Sanofi, Regeneron from selling cholesterol drug Jan 05 2017
    Sanofi Announces Soliqua™ 100/33 Now Available in the U.S. ​ Jan 04 2017
    Sanofi, Regeneron lose bid to overturn Amgen win in patent case Jan 03 2017
    Philippine FDA orders Sanofi to take down dengue vaccine ads Jan 03 2017
    Sanofi Pasteur and MSD end joint vaccines business in Europe Jan 02 2017
    Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017 Jan 02 2017
    Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017 Jan 02 2017
    U.S. FTC requires divestitures in $13.53 billion Boehringer-Sanofi deal Dec 28 2016
    Boehringer to divest US assets to win approval for Sanofi deal Dec 28 2016
    Boehringer to divest US assets to win approval for Sanofi deal Dec 28 2016
    Sanofi sues Novo Nordisk over diabetes drugs in the U.S. Dec 27 2016
    Actelion re-enters talks with J&J, sidelining Sanofi Dec 22 2016
    Actelion re-enters talks with J&J, sidelining Sanofi Dec 22 2016
    Actelion re-enters talks with J&J, sidelining Sanofi Dec 22 2016
    Actelion shares gain on report of progress in Sanofi talks Dec 21 2016
    Sanofi's takeover talks with Actelion progressing - source Dec 20 2016
    M&A talk helps European shares stay close to 11-month highs Dec 16 2016
    Actelion's shares jump on report of Sanofi deal nearing Dec 16 2016
    Actelion's shares jump on report of Sanofi deal nearing Dec 16 2016
    Actelion's shares jump on report of Sanofi deal nearing Dec 16 2016
    Sanofi discusses $275 per Actelion share for potential deal - Bloomberg Dec 15 2016
    Actelion talking to Sanofi after J&J exit Dec 14 2016
    Actelion talking to Sanofi after J&J exit Dec 14 2016
    Families bring class action against French drug maker Sanofi Dec 13 2016
    France's Sanofi faces class action suit over epilepsy drug Dec 13 2016
    France's Sanofi faces class action suit over epilepsy drug Dec 12 2016
    Sanofi exploring bid for Actelion amid J&J talks - Bloomberg Dec 05 2016
    Actelion's ambitious independent-minded CEO will drive up takeover price Nov 28 2016
    Sanofi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes Nov 21 2016
    Sanofi, GSK expect further price pressure, more M&A under Trump Nov 15 2016
    Sanofi Receives CHMP Recommendation for Approval of SuliquaTM in the EU ​ Nov 11 2016
    Drugmakers under fire for possible U.S. price fixing Nov 03 2016
    Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational... Oct 28 2016
    Sanofi Announces Strong Q3 2016 Results Oct 28 2016
    Sanofi Announces Strong Q3 2016 Results Oct 27 2016
    Sanofi Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Vaccine Research Oct 27 2016
    Availability of the Pre-quarterly Results Communication ? Oct 12 2016
    New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on... Oct 05 2016
    Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data... Oct 01 2016
    Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare Sep 30 2016
    Understanding diabetes in the developing world Sep 29 2016
    BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika ​ Sep 26 2016
    Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review... Sep 26 2016
    Sanofi may win U.S. approval of $3 bln eczema drug by March Sep 26 2016
    Hard to swallow: emerging markets get tougher for drugmakers Sep 22 2016
    Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis... Sep 16 2016
    Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis... Sep 16 2016
    Results from 1,000-Patient, Global Real-World Patient-Reported Outcomes Study of Sanofi Genzyme’s... Sep 15 2016
    Sanofi, Google parent form $500 mln diabetes joint venture Sep 12 2016
    Sanofi, Google launch diabetes joint venture Sep 11 2016
    Pfizer boosts cancer drug roster with $14 billion Medivation deal Aug 22 2016
    Pfizer to acquire Medivation for $14 billion Aug 22 2016
    EU clears Sanofi acquisition of Boehringer division Aug 04 2016
    Sanofi sticks to targets after profit drop Jul 29 2016
    Buyout target Medivation says cancer drug could be 'best in class' Jul 06 2016
    Buyout target Medivation says cancer drug could be "best in class" Jul 06 2016
    Medivation rejects 2nd Sanofi bid but keeps merger door open Jul 05 2016
    Medivation agrees to open its books to Sanofi Jul 05 2016
    France's Sanofi seeks to sack board of US takeover prey May 25 2016
    FDA staff question usefulness of Sanofi diabetes drugs May 23 2016
    FDA staff question dosing of Sanofi combination diabetes drug May 23 2016
    Sanofi recalls some batches of painkiller Combiflam in India May 12 2016
    Sanofi, Amgen cholesterol drugs win UK backing after price cuts May 05 2016
    EXCLUSIVE: Pfizer approaches Medivation about potential takeover -sources May 03 2016
    First U.S. Zika virus transmission reported, attributed to sex Feb 03 2016
    Exclusive: Lazard works with Sanofi on $12.7 billion animal health unit deal - sources Nov 27 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)